Rapid Communication
Copyright ©2008 The WJG Press and Baishideng.
World J Gastroenterol. Apr 14, 2008; 14(14): 2187-2193
Published online Apr 14, 2008. doi: 10.3748/wjg.14.2187
Table 1 Demographic and outcome data of patients treated with flavonoids and controls
Treated (n = 31)Controls (n = 56)P value
Males/females17/1431/25> 0.9
Age (yr) median (IQR)74 (68-80)77 (69-82)0.35
BMI (kg/m²) median (IQR)26.1 (24.4-28.2) (n = 28)27.5 (25.0-30.3) (n = 45)0.32
Resected colon cancer/polypectomy14/1722/340.65
Surveillance colonoscopy/no22/924/320.0141
Surveillance time by colonoscopy
Years: Median (IQR)3.5 (3-4.75) (n = 22)3.0 (2-3) (n = 24)0.0191
Surveillance time by questionnaire
Years: Median (IQR)3.6 (3.1-4.7)2.9 (2.5-3.4)0.0041
Cancer recurrence/no0/203/180.23
Polyp recurrence/no5/157/140.73
Neoplasia recurrence/no5/1510/110.20
Smoker/non-smoker2/276/480.71
Alcohol/no24/533/200.08
Black tea/no16/1527/26> 0.9
Green tea/no13/1621/27> 0.9
Fruit intake < 3/≥ 3 × weekly8/2017/350.80
Vegetable intake < 3/≥ 3 × weekly15/1329/220.82
Aspirin use/no11/2018/370.82
NSAID use/no2/293/52> 0.9
Colon cancer in family/no1/306/490.41
Adenomas in family/no2/291/540.29